Innovative biomarker development for personalized medicine in breast cancer care

Biomarkers in Medicine

Volumn 5, Issue 1, 2011, Pages 73-78

  Zografos, George C ^a   Roukos, Dimitrios H ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

breast cancer; cancer genome; commercialization; evidence; genetics; genomics; innovation; molecular diagnostics; standard market; test

Indexed keywords

AROMATASE INHIBITOR; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB;

BREAST CANCER; CANCER MORTALITY; CANCER RESISTANCE; CANCER RISK; CANCER SCREENING; CYP2D6 GENE; EDITORIAL; FAMILIAL CANCER; GENE; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SCREENING; GENOTYPE; HIGH RISK PATIENT; HUMAN; MAMMOGRAPHY; MASTECTOMY; MEDICAL DECISION MAKING; OVARY CANCER; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHARMACOGENOMICS; PREDICTION; PRIMARY PREVENTION; PROGNOSIS; SALPINGOOOPHORECTOMY; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; FEMALE; GENETIC TESTING; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; MUTATION; PROGNOSIS; RISK; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79951785048     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.10.116     Document Type: Editorial

References (42)

1. Kamangar F, Dores GM, Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. (Pubitemid 46655601)
2. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J. Clin. 60(5), 277-300 (2010)
3. Goldhirsch A, Ingle JN, Gelber RD et al.: Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann. Oncol. 20(8), 1319-1329 (2009).
4. Stafford RS, Wagner TH, Lavori PW: New, but not improved? Incorporating comparative-effectiveness information into FDA labeling. N. Engl. J. Med. 361(13), 1230-1233 (2009).
5. Ziogas D, Roukos DH: Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. Ann. Surg. Oncol. 16(7), 1771-1782 (2009).
6. Domchek SM, Friebel TM, Singer CF et al.: Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304(9), 967-975 (2010).
7. Welch GH: Screening mammography - a long run for a short slide? N. Engl. J. Med. 363, 1276-1278 (2010).
8. Early Breast Cancer Trialists Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 365(9472), 1687-1717 (2005).
9. Huang RS, Ratain MJ: Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J. Clin. 59(1), 42-55 (2009).
10. Baselga J, Swain SM: Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer 9(7), 463-475 (2009).
11. Slamon DJ, Leyland-Jones B, Shak S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11), 783-792 (2001). (Pubitemid 32222155)
12. Burstein HJ: The distinctive nature of HER2-positive breast cancers. N. Engl. J. Med. 353(16), 1652-1654 (2005). (Pubitemid 41464703)
13. Dahabreh IJ, Linardou H, Siannis F, Fountzilas G, Murray S: Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist 13(6), 620-630 (2008). (Pubitemid 351904907)
14. Roukos DH: Complete genome sequencing and network modeling to overcome trastuzumab resistance. Pharmacogenomics 11(8), 1039-1043 (2010).
15. Perou CM, Sorlie T, Eisen MB et al.: Molecular portraits of human breast tumours. Nature 406(6797), 747-752 (2000).
16. Paik S, Shak S, Tang G et al.: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351(27), 2817-2826 (2004). (Pubitemid 40051905)
17. van de Vijver MJ, He YD, vant Veer LJ et al.: A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347(25), 1999-2009 (2002). (Pubitemid 35461656)
18. Roukos DH, Ziogas DE, Katsios C: Multigene assays and isolated tumor cells for early breast cancer treatment: time for bionetworks. Expert Rev. Anticancer Ther. 10(8), 1187-1195 (2010).
19. Manolio TA: Genomewide association studies and assessment of the risk of disease. N. Engl. J. Med. 363(2), 166-176 (2010).
20. Frazer KA, Ballinger DG, Cox DR et al.: A second generation human haplotype map of over 3.1 million SNPs. Nature 449(7164), 851-861 (2007). (Pubitemid 47598626)
21. Wacholder S, Hartge P, Prentice R et al.: Performance of common genetic variants in breast-cancer risk models. N. Engl. J. Med. 362(11), 986-993 (2010).
22. Annes JP, Giovanni MA, Murray MF: Risks of presymptomatic direct-to-consumer genetic testing. N. Engl. J. Med. 363(12), 1100-1101 (2010).
23. Manolio TA, Collins FS, Cox NJ et al.: Finding the missing heritability of complex diseases. Nature, 461(7265), 747-753 (2009).
24. Schadt EE: Molecular networks as sensors and drivers of common human diseases. Nature 461(7261), 218-223 (2009).
25. Roukos DH, Katsios C, Liakakos T: Genotype-phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert Rev. Mol. Diagn. 10(5), 541-545 (2010).
26. Roukos DH: Systems medicine: a real approach for future personalized oncology? Pharmacogenomics 11(3), 283-287 (2010).
27. Ng AC: Integrative systems biology and networks in autophagy. Semin. Immunopathol. 32(4), 355-361 (2010).
28. Werner T: Next generation sequencing in functional genomics. Brief Bioinform. 11(5), 499-511 (2010).78 future science group
29. Heard E, Tishkoff S, Todd JA et al.: Ten years of genetics and genomics: what have we achieved and where are we heading? Nat. Rev. Genet. 11(10), 723-733 (2010).
30. Breitkreutz A, Choi H, Sharom JR et al.: A global protein kinase and phosphatase interaction network in yeast. Science 328(5981), 1043-1046 (2010).
31. Ding L, Ellis MJ, Li S et al.: Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464(7291), 999-1005 (2010).
32. Venter JC: Multiple personal genomes await. Nature 464(7289), 676-677 (2010).
33. Roukos DH: Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. Pharmacogenomics J. DOI: 10.1038/tpj.2010.81 (2010) (Epub ahead of print).
34. Barnett GC, Shah M, Redman K et al.: Risk factors for the incidence of breast cancer: do they affect survival from the disease? J. Clin. Oncol. 26(20), 3310-3316 (2008).
35. Roukos DH: Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management? Expert Rev. Mol. Diagn. 10(3), 247-250 (2010).
36. Wood SN: Statistical inference for noisy nonlinear ecological dynamic systems. Nature 466(7310), 1102-1104 (2010).
37. Hudson TJ, Anderson W, Artez A et al.: International network of cancer genome projects. Nature 464(7291), 993-998 (2010).
38. Katsnelson A: Genomics goes beyond DNA sequence. Nature 465(7295), 145 (2010).
39. Roukos DH: Next-generation sequencing and epigenome technologies: potential medical applications. Expert Rev. Med. Devices 7(6), 723-726 (2010).
40. Roukos DH: Novel clinico-genome network modeling for revolutionizing genotype- phenotype-based personalized cancer care. Expert Rev. Mol. Diagn. 10(1), 33-48 (2010).
41. Roukos DH: Next-generation, genome sequencing-based biomarkers: concerns and challenges for medical practice. Biomark. Med. 4(4), 583-586 (2010).
42. National Comprehensive Cancer Network: Guidelines for treatment of cancer by site www.nccn.org/professionals/physician-gls/ pdf/breast.pdf